Atrium Therapeutics, Inc.RNA

Spin-off from Avidity Biosciences, Inc. · Feb 27, 2026 · Nasdaq

one share of Atrium common stock for every ten shares of Avidity common stock

Documents

Both companies today

Moat ratings, quality scores and fair value estimates are MoatScope research opinions and refresh with the data pipeline. Price / FV below 1.00× means the shares trade under our base-case estimate.

What is being separated

Atrium Therapeutics holds the early-stage precision cardiology programs Avidity Biosciences carved out immediately before Novartis completed its acquisition of Avidity on February 27, 2026. Atrium inherited Avidity's Nasdaq symbol, RNA; Avidity's late-stage neuromuscular RNA programs went to Novartis with the rest of the company.

Stated rationaleThe spin-off was a condition of the Novartis merger agreement: Avidity shareholders kept the programs Novartis was not buying as a separate public company rather than losing them in the sale.

The four questions

Not investment advice. Terms are as stated in the latest filing; spin-off shares are often thinly covered and volatile in their first months.